Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 441-445 , May 2008

Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the “glucose-corrected” SUV

  • Mohiuddin Hadi

      Affiliations

    • Department of Radiology, University of California, San Francisco, CA, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, UCSF, San Francisco, CA 94158, USA. Tel.: +1 301 476 0567; fax: +1 415 353 9421.
    • ,
  • Stephen L. Bacharach

      Affiliations

    • Department of Radiology, University of California, San Francisco, CA, USA
    • ,
  • Millie Whatley

      Affiliations

    • Nuclear Medicine Department, NIH, Bethesda, MD, USA
    • ,
  • Steven K. Libutti

      Affiliations

    • Surgical Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Stephen E. Straus

      Affiliations

    • Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
    • ,
  • V. Koneti Rao

      Affiliations

    • Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
    • ,
  • Robert Wesley

      Affiliations

    • Biostatistics Service, Clinical Center, NIH, Bethesda, MD, USA
    • ,
  • Jorge A. Carrasquillo

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA

Received 14 June 2007 ,Revised 29 January 2008 ,Accepted 11 February 2008.

References 

  1. Hustinx R, Benard F, et al. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35–46
  2. Rohren EM, Turkington TG, et al. Clinical applications of PET in oncology. Radiology. 2004;231(2):305–332
  3. Bastiaannet E, Groen H, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30(1):83–101
  4. Jadvar H, Gamie S, et al. Musculoskeletal system. Semin Nucl Med. 2004;34(4):254–261
  5. Vansteenkiste J, Fischer BM, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;5(9):531–540
  6. Weber WA, Schwaiger M, et al. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27(7):683–687
  7. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol. 2000;27(7):643–646
  8. Minn H, Leskinen-Kallio S, et al. [18F]Fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr. 1993;17(1):115–123
  9. Paquet N, Albert A, et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45(5):784–788
  10. Sokoloff L, Reivich M, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28(5):897–916
  11. O'Rahilly S, Burnett MA, et al. Haemolysis affects insulin but not C-peptide immunoassay. Diabetologia. 1987;30(6):394–396
  12. Randall AG, Garcia-Webb P, et al. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem. 1990;27(Pt 4):345–352
  13. Sapin R, Ongagna JC, et al. Insulin measurements in haemolysed serum: influence of insulinase inhibitors. Clin Chim Acta. 1998;274(1):111–117
  14. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989;27(5):409–437
  15. Reivich M, Kuhl D, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44(1):127–137
  16. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun. 1996;17(10):890–894
  17. Hallett WA, Marsden PK, et al. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med. 2001;28(7):919–922
  18. Freedman NM, Sundaram SK, et al. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging. 2003;30(1):46–53
  19. Minn H, Zasadny KR, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology. 1995;196(1):167–173
  20. Nakamoto Y, Zasadny KR, et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol. 2002;4(2):171–178
  21. Stahl A, Ott K, et al. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging. 2004;31(11):1471–1478
  22. Langen KJ, Braun U, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34(3):355–359
  23. Lindholm P, Minn H, et al. Influence of the blood glucose concentration on FDG uptake in cancer — a PET study. J Nucl Med. 1993;34(1):1–6
  24. Crippa F, Gavazzi C, et al. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori. 1997;83(4):748–752
  25. Yokoyama I, Inoue Y, et al. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET. J Nucl Med. 2003;44(10):1592–1598
  26. Hoekstra CJ, Hoekstra OS, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med. 2002;43(10):1304–1309
  27. Krak NC, van der Hoeven JJ, et al. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging. 2003;30(5):674–681
  28. Roelcke U, Blasberg RG, et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med. 1998;39(5):879–884
  29. Hassen K. Oscillations in the blood sugar in fasting normal persons. Acta Med Scand Suppl. 1923;4:27–33
  30. Polonsky KS, Given BD, et al. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81(2):442–448
  31. Lacher DA, Hughes JP, et al. Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey. Clin Chem. 2005;51(2):450–452
  32. Sebastian-Gambaro MA, Liron-Hernandez FJ, et al. Intra- and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem. 1997;35(11):845–852
  33. Chen H, Sullivan G, et al. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes. 2005;54(7):1914–1925

☆ One of the co-authors, Dr Stephen E. Straus is deceased; however, he was involved in and had approved an earlier version of this manuscript.

PII: S0969-8051(08)00065-6

doi: 10.1016/j.nucmedbio.2008.02.007

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 441-445 , May 2008

Article Tools